Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Immune cell boost could enable lasting vaccine protection

A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...

Genes influence when babies start walking

Genetics accounts for about a quarter of the differences in when children take their first steps,...

Novel glycopeptide antibiotic candidate shows promise

Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...

Content from other channels on our network

Food sector involvement with NZ waste reduction initiative

Beefing up the flavour of cultured meat

New wave system for picking fruit

World Food Safety Day: engineering better food safety

World Food Safety Day: food safety system at work

Navigating SIF logic solver selection: Why the Moore Industries SLA stands out

Heat exchangers expand ginger beer production in Bundaberg

Tackling the evolving cyber challenges in our industrial sector

Yokogawa celebrates 50 years of CENTUM with next-gen release

World-first Australian solution to treat wastewater at a major beverages company

Refilled drink dispenser reduces corporate plastic waste

Food waste action reduces methane emissions

City of Gosnells retains Gold for Waterwise initiatives

VicReturn partners with Sports Environment Alliance

Aussie wine brand addresses overlooked recycling flaw